Please Wait.....
Report
Asia Pacific Dengue Treatment Market
Market Report I 2024-06-01 I 210 Pages I Data Bridge Market Research
Asia-Pacific dengue treatment market is expected to reach USD 1,069.30 million by 2031, from USD 418.71 million in 2023, growing with a CAGR of 12.4% in the forecast period of 2024 to 2031.
Market Segmentation:
Asia-Pacific Dengue Treatment Market, By Strains (DENV-2, DENV-3, DENV-1, DENV-4, and Others), Type (Vaccines and Acetaminophen), Severity (Mild to Moderate Dengue and Severe Dengue), Route of Administration (Parenteral and Oral), Mode of Purchase (Prescription and Over-the-Counter (OTC)), Gender (Male and Female), Age (Adult, Pediatric, and Geriatric), End User (Hospital, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Countries (Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2031
Overview of Asia-Pacific Dengue Treatment Market Dynamics:
Driver
- Rising dengue incidence rate result in the demand for effective treatment
Restrain
- Delay in the approval process of vaccines
Opportunity
- Growing number of pipeline vaccines for dengue treatment
Market Players:
The key market players operating in the Asia-Pacific dengue treatment market are listed below:
- Sanofi
- Takeda Pharmaceutical Company Limited
- Viatris Inc.
- Johnson & Johnson
- GSK plc.
- Perrigo Company PLC
- Baxter
- Fresenius Kabi USA
- Pfizer
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceuticals USA, Inc.
- Aurobindo Pharma
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF THE ASIA-PACIFIC DENGUE TREATMENT MARKET 22
1.4 CURRENCY AND PRICING 24
1.5 LIMITATIONS 24
1.6 MARKETS COVERED 25
2 MARKET SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 DBMR TRIPOD DATA VALIDATION MODEL 31
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.6 MULTIVARIATE MODELLING 35
2.7 MARKET APPLICATION COVERAGE GRID 36
2.8 PRODUCT LIFELINE CURVE 37
2.9 DBMR MARKET POSITION GRID 38
2.10 VENDOR SHARE ANALYSIS 39
2.11 SECONDARY SOURCES 40
2.12 ASSUMPTIONS 40
3 EXECUTIVE SUMMARY 41
4 PREMIUM INSIGHTS 44
4.1 PESTEL ANALYSIS 45
4.2 PORTER'S FIVE FORCES 46
5 ASIA-PACIFIC DENGUE TREATMENT MARKET: REGULATIONS 47
5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT 48
5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT 48
5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK 49
5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE 49
5.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK 50
?
6 MARKET OVERVIEW 51
6.1 DRIVERS 53
6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT 53
6.1.2 RISING WAVE OF DENGUE VACCINE LAUNCHES 53
6.1.3 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS 54
6.1.4 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES 55
6.2 RESTRAINTS 56
6.2.1 DELAY IN THE APPROVAL PROCESS OF VACCINES 56
6.2.2 LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE 57
6.2.3 DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE 58
6.3 OPPORTUNITIES 59
6.3.1 STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET 59
6.3.2 GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT 59
6.3.3 RISING R&D INVESTMENT AND ACTIVITIES 60
6.4 CHALLENGES 61
6.4.1 HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS 61
6.4.2 HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS 61
7 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS 63
7.1 OVERVIEW 64
7.2 DENV-2 67
7.3 DENV-3 67
7.4 DENV-1 68
7.5 DENV-4 68
7.6 OTHERS 69
8 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TYPE 70
8.1 OVERVIEW 71
8.2 VACCINES 74
8.2.1 DENGVAXIA (CYD-TDV) 75
8.2.2 QDENGA 75
8.3 ACETAMINOPHEN 75
8.3.1 PARENTERAL 76
8.3.2 ORAL 76
8.3.3 OTHER 76
?
9 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY SEVERITY 77
9.1 OVERVIEW 78
9.2 MILD TO MODERATE DENGUE 81
9.3 SEVERE DENGUE 81
10 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 82
10.1 OVERVIEW 83
10.2 PARENTERAL 86
10.2.1 SUB-CUTANEOUS 86
10.2.2 INTRAVENOUS 86
10.3 ORAL 87
10.3.1 TABLET 87
10.3.2 CAPSULES 87
10.3.3 OTHERS 87
11 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY MODE OF PURCHASE 88
11.1 OVERVIEW 89
11.2 PRESCRIPTION 92
11.3 OVER-THE-COUNTER (OTC) 92
12 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY GENDER 93
12.1 OVERVIEW 94
12.2 MALE 97
12.3 FEMALE 97
13 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY AGE 98
13.1 OVERVIEW 99
13.2 ADULT 102
13.3 PEDIATRIC 102
13.4 GERIATRIC 103
14 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY END USER 104
14.1 OVERVIEW 105
14.2 HOSPITAL 108
14.3 SPECIALTY CLINICS 108
14.4 HOME HEALTHCARE 109
14.5 OTHERS 109
?
15 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 110
15.1 OVERVIEW 111
15.2 RETAIL PHARMACIES 114
15.3 HOSPITAL PHARMACIES 114
15.4 ONLINE PHARMACIES 115
16 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY REGION 116
16.1 ASIA-PACIFIC 120
16.1.1 INDIA 126
16.1.2 CHINA 131
16.1.3 JAPAN 136
16.1.4 INDONESIA 141
16.1.5 MALAYSIA 146
16.1.6 THAILAND 151
16.1.7 AUSTRALIA 156
16.1.8 SOUTH KOREA 161
16.1.9 SINGAPORE 166
16.1.10 PHILIPPINES 171
16.1.11 REST OF ASIA-PACIFIC 176
17 ASIA-PACIFIC DENGUE TREATMENT MARKET: COMPANY LANDSCAPE 177
17.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 177
18 SWOT ANALYSIS 178
19 COMPANY PROFILE 179
19.1 SANOFI 179
19.1.1 COMPANY SNAPSHOT 179
19.1.2 REVENUE ANALYSIS 179
19.1.3 COMPANY SHARE ANALYSIS 180
19.1.4 PRODUCT PORTFOLIO 180
19.1.5 RECENT DEVELOPMENTS 180
19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED 181
19.2.1 COMPANY SNAPSHOT 181
19.2.2 REVENUE ANALYSIS 181
19.2.3 COMPANY SHARE ANALYSIS 182
19.2.4 PRODUCT PORTFOLIO 182
19.2.5 RECENT DEVELOPMENTS 182
?
19.3 VIATRIS INC. 184
19.3.1 COMPANY SNAPSHOT 184
19.3.2 REVENUE ANALYSIS 185
19.3.3 COMPANY SHARE ANALYSIS 185
19.3.4 PRODUCT PORTFOLIO 185
19.3.5 RECENT DEVELOPMENTS 186
19.4 JOHNSON & JOHNSON SERVICES, INC. 187
19.4.1 COMPANY SNAPSHOT 187
19.4.2 REVENUE ANALYSIS 187
19.4.3 COMPANY SHARE ANALYSIS 188
19.4.4 PRODUCT PORTFOLIO 188
19.4.5 RECENT DEVELOPMENT 188
19.5 GSK PLC. 190
19.5.1 COMPANY SNAPSHOT 190
19.5.2 REVENUE ANALYSIS 190
19.5.3 COMPANY SHARE ANALYSIS 191
19.5.4 PRODUCT PORTFOLIO 191
19.5.5 RECENT DEVELOPMENTS 191
19.6 AUROBINDO PHARMA 192
19.6.1 COMPANY SNAPSHOT 192
19.6.2 REVENUE ANALYSIS 192
19.6.3 PRODUCT PORTFOLIO 193
19.7 BAXTER 194
19.7.1 COMPANY SNAPSHOT 194
19.7.2 REVENUE ANALYSIS 194
19.7.3 PRODUCT PORTFOLIO 195
19.8 FRESENIUS KABI USA 196
19.8.1 COMPANY SNAPSHOT 196
19.8.2 PRODUCT PORTFOLIO 196
19.8.3 RECENT DEVELOPMENTS 196
19.9 HIKMA PHARMACEUTICALS 197
19.9.1 COMPANY SNAPSHOT 197
19.9.2 REVENUE ANALYSIS 197
19.9.3 PRODUCT PORTFOLIO 198
19.9.4 RECENT DEVELOPMENT 198
19.10 PERRIGO COMPANY PLC 199
19.10.1 COMPANY SNAPSHOT 199
19.10.2 REVENUE ANALYSIS 199
19.10.3 PRODUCT PORTFOLIO 200
19.10.4 RECENT DEVELOPMENT 200
19.11 PFIZER INC. 201
19.11.1 COMPANY SNAPSHOT 201
19.11.2 REVENUE ANALYSIS 201
19.11.3 PRODUCT PORTFOLIO 202
19.11.4 RECENT DEVELOPMENTS 202
19.12 SUN PHARMACEUTICAL INDUSTRIES LTD 203
19.12.1 COMPANY SNAPSHOT 203
19.12.2 REVENUE ANALYSIS 204
19.12.3 PRODUCT PORTFOLIO 204
19.12.4 RECENT DEVELOPMENT 204
19.13 TEVA PHARMACEUTICALS USA, INC. 205
19.13.1 COMPANY SNAPSHOT 205
19.13.2 REVENUE ANALYSIS 205
19.13.3 PRODUCT PORTFOLIO 206
19.13.4 RECENT DEVELOPMENT 206
20 QUESTIONNAIRE 207
21 RELATED REPORTS 210
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security